

**In the Claims**

Applicant has submitted a new complete claim set showing replacement claims.

1. (Previously Presented) A method for treating a subject having an inflammatory joint disorder comprising

administering to a subject in need of such treatment a therapeutically effective amount of a cadherin-11 inhibitory agent

wherein the cadherin-11 inhibitory agent is an antibody to cadherin-11 that inhibits binding of cadherin-11 to a cadherin-11 counter-receptor.

2. (Canceled)

3. (Original) The method of claim 1, wherein the inflammatory joint disorder is an autoimmune disease.

4. (Canceled)

5. (Original) The method of claim 1, wherein the cadherin-11 inhibitory agent is administered locally to a synovium of the subject.

6. (Original) The method of claim 1, wherein the cadherin-11 inhibitory agent binds selectively to cadherin-11.

7 -15. (Canceled)

16. (Original) The method of claim 1, wherein the cadherin-11 counter-receptor is selected from the group consisting of a cadherin, an integrin, a carbohydrate and an immunoglobulin family member.

17 -43. (Canceled)

44. (Previously presented) A method for treating a subject having an inflammatory joint disorder comprising  
administering to a subject in need of such treatment a therapeutically effective amount of an agent that is an antibody to cadherin-11 which modulates a cellular function in a cadherin-11 expressing cell.

45. (Original) The method of claim 44, wherein the cellular function is selected from the group consisting of cell proliferation, factor secretion, apoptosis, migration and attachment.

46 – 49 (Canceled)

50. (Previously Presented) The method of claim 1, wherein the inflammatory joint disorder is chronic synovitis.

51. (Previously Presented) The method of claim 3, wherein the autoimmune disease is rheumatoid arthritis.

52. (Previously Presented) The method of claim 1, wherein cadherin-11 and the cadherin-11 counter-receptor are expressed by separate cells.

53. (Previously Presented) The method of claim 1, wherein cadherin-11 is expressed by a cell selected from the group consisting of a type A synoviocyte, a type B synoviocyte, a synovial derived fibroblast, a synovial membrane lining cell, an osteoblast, a cartilage-derived cell and an invasive pannus-derived cell.

54. (Previously Presented) The method of claim 1, wherein the cadherin-11 counter-receptor is expressed by a cell selected from the group consisting of a type A synoviocyte, a type B synoviocyte, a synovial derived fibroblast, a synovial membrane lining cell, an osteoblast, a

cartilage-derived cell, an invasive pannus-derived cell, a T lymphocyte, a B lymphocyte, a mast cell, a macrophage, a plasma cell, a dendritic cell and a natural killer cell.

55. (Previously Presented) The method of claim 1, wherein the cadherin-11 counter-receptor is a component of an extracellular matrix of a tissue, a cartilage or a bone.

56. (Previously Presented) The method of claim 1, wherein the cadherin-11 counter-receptor is a molecule secreted by a cell.

57. (New) The method of claim 1, wherein administering is administering systemically.

58. (New) The method of claim 44, wherein administering is administering systemically.